Core Viewpoint - 泰德医药's stock has experienced a significant decline since its IPO, currently trading at 28.04 HKD, down 6.53% on the day and 8.37% since listing [1] Group 1: Stock Performance - The stock reached an intraday low of 26.76 HKD, marking its lowest price since the IPO [1] - The stock is currently in a state of decline, having fallen below its initial offering price [1] Group 2: IPO Details - 泰德医药 was listed on the Hong Kong Stock Exchange on June 30, 2025, with a final offer price of 30.6 HKD [1] - A total of 16,800,000 H-shares were issued, with 8,400,000 shares allocated for public offering in Hong Kong and 8,400,000 shares for international offering [1] Group 3: Financials - The total proceeds from the IPO amounted to 514.08 million HKD, with net proceeds of 428.77 million HKD after deducting estimated listing expenses of 85.31 million HKD [1] Group 4: Underwriters and Investors - The joint sponsors and underwriters for the IPO include Morgan Stanley, CITIC Securities, and others [1] - Key cornerstone investors for 泰德医药 include 石药 and Welight Capital [1]
港股破发股泰德医药跌6.53%创新低 石药等为基石